Last reviewed · How we verify

NCT06763081: PGx-SImBA

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation

Recruiting now Last updated 8 September 2025
What this trial tests

trial testing Not applicable- observational study in Behavioral Activation in 160 participants. Currently enrolling.

Timeline
1 March 2025
Primary endpoint
31 December 2028
31 December 2030

Quick facts

Lead sponsorUniversity of Manitoba
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment160
Start date1 March 2025
Primary completion31 December 2028
Estimated completion31 December 2030
Sites2 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

University of Manitoba

Who can join

Adults 6 to 24, any sex, with Behavioral Activation or Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to identify and validate a panel of genetic markers associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioural activation in children and youth with major depressive disorder (MDD), anxiety disorders, or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Not applicable- observational study

Trials testing the same drug.

Other University of Manitoba trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06763081.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing